文献速递其他结缔组织病

对皮肌炎特异性自身抗原TIF1γ的免疫应答可诱导实验性肌炎

Immune response to dermatomyositis-specific autoantigen, transcriptional intermediary factor 1γ can result in experimental myositis.
PubMed 文献 · Ann Rheum Dis · 2021-04-02

该研究用重组人TIF1γ蛋白免疫野生型及多种基因敲除小鼠,发现可诱导以肌纤维坏死/萎缩和CD8+ T细胞浸润为特征的实验性肌炎,且该过程依赖CD8+ T细胞和I型干扰素,而不依赖CD4+ T细胞、B细胞或抗体;托法替尼可抑制该肌炎。

要点

  • TIF1γ免疫可诱导野生型小鼠发生实验性肌炎,伴CD8+ T细胞浸润。
  • 肌炎发生依赖CD8+ T细胞和I型干扰素,不依赖B细胞或抗体。
  • JAK抑制剂托法替尼可抑制TIF1γ诱导的肌炎。

核心结论

  • TIF1γ具有足够免疫原性可诱导实验性肌炎,其中CD8+ T细胞和I型干扰素是必需的,而CD4+ T细胞、B细胞或抗体不是必需的。

研究设计与样本

  • 用重组人TIF1γ全蛋白免疫野生型、β2-微球蛋白敲除、穿孔素敲除、Igμ敲除和IFNAR敲除小鼠。
  • 进行淋巴结T细胞胸苷掺入实验,血浆免疫沉淀后western blot及ELISA分析,股肌组织学和免疫组化评估。
  • 将淋巴结来源CD8+或CD4+ T细胞或血浆纯化IgG过继转移至 naïve 小鼠。
  • 对TIF1γ免疫小鼠使用抗CD8清除抗体和JAK抑制剂托法替尼治疗。

主要发现

  • 野生型小鼠免疫后成功诱导实验性肌炎,表现为肌纤维坏死/萎缩伴CD8+ T细胞浸润,并检测到TIF1γ特异性T细胞及抗人/鼠TIF1γ IgG抗体。
  • β2-微球蛋白敲除、穿孔素敲除、CD8清除或IFNAR敲除小鼠的肌炎发生率和严重程度显著降低,而Igμ敲除小鼠正常发生肌炎。
  • 过继转移CD8+ T细胞可在受者中诱导肌炎,而转移CD4+ T细胞或IgG则不能。
  • 托法替尼治疗可抑制TIF1γ诱导的肌炎。

临床怎么用

  • 该小鼠模型提示CD8+ T细胞和I型干扰素在TIF1γ相关肌炎中的关键作用,或为皮肌炎病理理解提供工具。
  • 托法替尼在模型中抑制肌炎的结果提示JAK抑制剂可能对该通路相关肌炎有潜在作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate whether autoimmunity to transcriptional intermediary factor 1 (TIF1)γ, a ubiquitous nuclear autoantigen for myositis-specific autoantibodies detected in patients with dermatomyositis (DM) is pathogenetic for inflammatory myopathy. METHODS: Wild-type, β2-microglobulin-null, perforin-null, Igμ-null and interferon α/β receptor (IFNAR)-null mice were immunised with recombinant human TIF1γ whole protein. A thymidine incorporation assay was performed using lymph node T cells from TIF1γ-immunised mice. Plasma was analysed using immunoprecipitation followed by western blot analysis and enzyme-linked immunosorbent assays. Femoral muscles were histologically and immunohistochemically evaluated. CD8+ or CD4+ T cells isolated from lymph node T cells or IgG purified from plasma were adoptively transferred to naïve mice. TIF1γ-immunised mice were treated with anti-CD8 depleting antibody and a Janus kinase inhibitor, tofacitinib. RESULTS: Immunisation with TIF1γ-induced experimental myositis presenting with necrosis/atrophy of muscle fibres accompanied by CD8+ T cell infiltration successfully in wild-type mice, in which TIF1γ-specific T cells and antihuman and murine TIF1γ IgG antibodies were detected. The incidence and severity of myositis were significantly lower in β₂-microglobulin-null, perforin-null, CD8-depleted or IFNAR-null mice, while Igμ-null mice developed myositis normally. Adoptive transfer of CD8+ T cells induced myositis in recipients, while transfer of CD4+ T cells or IgG did not. Treatment with tofacitinib inhibited TIF1γ-induced myositis. CONCLUSIONS: Here we show that TIF1γ is immunogenic enough to cause experimental myositis, in which CD8+ T cells and type I interferons, but not CD4+ T cells, B cells or antibodies, are required. This murine model would be a tool for understanding the pathologies of DM.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Okiyama N, Ichimura Y, Shobo M, et al. Immune response to dermatomyositis-specific autoantigen, transcriptional intermediary factor 1γ can result in experimental myositis. Ann Rheum Dis. 2021. PMID: 33811031. doi:10.1136/annrheumdis-2020-218661

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。